Study completed October 5th, 2022. Results presented at 2023 Union World Conference on Lung Health in Paris. "TBA-7371 was well tolerated and showed significant dose-dependent bactericidal activity with 14 days of treatment in patients with drug-susceptible pulmonary tuberculosis. TBA-7371 could have significant potential in the treatment of TB." Quoted from Bill & Melinda Gates Medical Research Institute LinkedIn Post.
| Arm | Intervention/treatment |
|---|---|
| Experimental: TBA-7371 100 mg QD | Drug: TBA-7371
Participants will receive TBA-7371 oral suspension 100 milligram (mg) once daily (QD) for 14 days. |
| Experimental: TBA-7371 100 mg BID | Drug: TBA-7371
Participants will receive TBA-7371 oral suspension 100 mg twice daily (BID) for 14 days. |
| Experimental: TBA-7371 200 mg QD | Drug: TBA-7371
Participants will receive TBA-7371 oral suspension 200 mg QD for 14 days. |
| Experimental: TBA-7371 100 mg TID | Drug: TBA-7371
Participants will receive TBA-7371 oral suspension 100 mg three times daily (TID) for 14 days. |
| Experimental: TBA-7371 400 mg QD | Drug: TBA-7371
Participants will receive TBA-7371 oral suspension 400 mg QD for 14 days. |
| Active Comparator: HRZE | Drug: HRZE
Participants will receive Isoniazid [H] / rifampicin [R] / pyrazinamide [Z] / ethambutol [E] (HRZE), a fixed dose combination (H: 75 mg / R: 150 mg / Z: 400 mg / E: 275 mg) tablet QD for 14 days. Other Name: Rifafour® e-275 |
Registry Link